RT Conference Proceedings
T1 Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
A1 Trigo, J.
A1 Cho, B. C.
A1 Park, K.
A1 Girard, N.
A1 Viteri, S.
A1 Garrido, P.
A1 Krebs, M. G.
A1 Thayu, M.
A1 Knoblauch, R. E.
A1 Xie, J.
A1 Bauml, J. M.
A1 Schnepp, R. W.
A1 Londhe, A.
A1 Mahadevia, P.
A1 Leighl, N.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-04-02
LK http://hdl.handle.net/10668/21888
UL http://hdl.handle.net/10668/21888
LA en
DS RISalud
RD Apr 12, 2025